F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat invasive fungal infections. The company discovered the orotomide class, which selectively targets a key enzyme in the de novo pyrimidine biosynthesis pathway. Its lead candidate, olorofim, is the first orotomide antifungal and an oral therapy with a mechanism distinct from existing antifungal classes. Olorofim has been awarded Breakthrough Therapy Designation by the FDA for multiple indications and is intended for serious invasive or rare fungal diseases where current treatments are inappropriate or ineffective. F2G plans to use the recent financing to complete late-stage development, seek regulatory approval, and prepare for U.S. commercialization of olorofim. Led by CEO Francesco Maria Lavino, the company operates in the UK, US, and Austria and has a 100%-owned subsidiary in Austria. F2G Ltd is a Manchester, UK-based clinical-stage biopharmaceutical company focused on discovery and development of novel therapies to treat potentially life‑threatening invasive fungal infections. Its lead asset is olorofim, a novel oral antifungal from a new class called the orotomides that selectively targets a key enzyme in the de novo pyrimidine biosynthesis pathway. Olorofim is in a Phase 2b open‑label study (NCT03583164) for patients with limited treatment options for invasive aspergillosis and other rare mold infections. F2G raised $70M in financing to advance late‑stage development and US commercialization of olorofim. The round was co‑led by new investors Forbion and Sofinnova Partners, with participation from existing backers including Novo Holdings, Morningside Ventures, Cowen Healthcare Investments and Advent Life Sciences. Nanna Lüneborg (Forbion) and Joe Anderson (Sofinnova Partners) will join the F2G board. In May 2022 the company entered a $480M strategic collaboration with Shionogi to develop and commercialize olorofim in Europe and Asia, which included $100M upfront, $380M in regulatory and commercialization milestones, and double‑digit royalties on sales. F2G operates in the UK, US and Austria and is led by CEO Francesco Maria Lavino. F2G discovers and develops antifungal therapies, including a new class of agents called the orotomides that target DHODH (dihydroorotate dehydrogenase). Its lead candidate, olorofim, is a novel antifungal in a Phase 2b open-label study focused on rare and resistant invasive fungal infections. Olorofim has been granted Breakthrough Therapy designation by the FDA (November 2019), the only antifungal to receive that status based on early tolerability and efficacy data. The company is advancing late-stage clinical programs and preparing for commercialisation. Proceeds from the recent financing will fund those clinical programs and organisational scale-up. Ian Nicholson is CEO of the company. F2G is a Manchester-based biotech focused on discovering and developing antifungal drugs. It is advancing F901318, a novel clinical-stage candidate for the treatment of invasive aspergillosis and other serious rare mould infections. The company planned a small PK Phase 2 clinical trial for F901318 in the second half of 2016 and aimed to begin pivotal registration trials for invasive aspergillosis in the first half of 2017 via an accelerated regulatory pathway. F2G raised $60M in financing led by Sectoral Asset Management to support development of its pipeline. Investors in the round include Novo A/S, Aisling Capital, Brace Pharma Capital and existing backers Advent Life Sciences LLP, Novartis Venture Fund, Sunstone Capital and Merifin Capital. Dr Maha Katabi and Dr Martin Edwards are joining the board as part of the financing, and Ian Nicholson serves as CEO.

Total raised

$291M

Funding rounds

4

Latest round

Equity

Latest activity

Sep 2024